Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Oramed Pharmaceuticals is a biotechnology business based in the US. Oramed Pharmaceuticals shares (ORMP) are listed on the NASDAQ and all prices are listed in US Dollars.
tastytrade
Finder Award
SoFi Invest
M1 Finance
| Latest market close | $4.02 |
|---|---|
| 52-week range | $1.81 - $13.73 |
| 50-day moving average | $2.83 |
| 200-day moving average | $5.35 |
| Wall St. target price | $13.77 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.75 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.02 from 2023-06-02
| 1 week (2023-05-26) | 1.52% |
|---|---|
| 1 month (2023-05-04) | 47.25% |
| 3 months (2023-03-03) | 87.85% |
| 6 months (2022-12-02) | -53.53% |
| 1 year (2022-06-02) | -14.29% |
|---|---|
| 2 years (2021-06-02) | -66.80% |
| 3 years (2020-06-04) | 17.20% |
| 5 years (2018-06-04) | 7.76 |
| Revenue TTM | $2.7 million |
|---|---|
| Gross profit TTM | $2.7 million |
| Return on assets TTM | -13.01% |
| Return on equity TTM | -19.64% |
| Profit margin | 0% |
| Book value | $3.78 |
| Market capitalisation | $160.9 million |
TTM: trailing 12 months
We're not expecting Oramed Pharmaceuticals to pay a dividend over the next 12 months.
Oramed Pharmaceuticals's shares were split on a 1:12 basis on 23 January 2013. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oramed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Oramed Pharmaceuticals shares which in turn could have impacted Oramed Pharmaceuticals's share price.
Over the last 12 months, Oramed Pharmaceuticals's shares have ranged in value from as little as $1.81 up to $13.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oramed Pharmaceuticals's is 1.8121. This would suggest that Oramed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. .
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.